Praxis Precision Medicines (PRAX) Stock Forecast & Price Target

Compare

907 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PRAX Analyst Ratings

Strong Buy

14 Buy

0 Hold

1 Sell

Based on 15 analysts giving stock ratings to

Praxis

Precision Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PRAX Stock 12 Month Forecast

Average Price Target

$455.86

▲(67.04% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $455.86 with a high forecast of $843.00 and a low forecast of $83.00. The average price target represents a 67.04% change from the last price of $272.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","439":"$439","844":"$844","236.5":"$236.5","641.5":"$641.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":843,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$843.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":455.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$455.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,236.5,439,641.5,844],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294.74,336.9138461538462,379.08769230769235,421.26153846153846,463.43538461538463,505.6092307692308,547.7830769230769,589.9569230769231,632.1307692307693,674.3046153846154,716.4784615384616,758.6523076923077,800.8261538461538,{"y":843,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294.74,307.13384615384615,319.5276923076923,331.9215384615385,344.31538461538463,356.70923076923077,369.1030769230769,381.49692307692305,393.89076923076925,406.2846153846154,418.67846153846153,431.07230769230773,443.4661538461538,{"y":455.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,294.74,278.4523076923077,262.1646153846154,245.8769230769231,229.58923076923077,213.30153846153848,197.01384615384617,180.72615384615386,164.43846153846155,148.15076923076924,131.86307692307693,115.57538461538462,99.28769230769234,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":294.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$843.00

Average Price Target$455.86

Lowest Price Target$83.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ami Fadia

Needham

$315→$460

Buy

68.56%

Upside

Reiterated

01/05/26

Praxis Precision price target raised to $460 from $315 at NeedhamPraxis Precision price target raised to $460 from $315 at Needham

Ritu Baral

TD Cowen

$353

Buy

29.35%

Upside

Reiterated

12/31/25

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX)

Rudy Li

Chardan Capital

$330

Buy

20.92%

Upside

Initiated

12/31/25

Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital

Joon Lee

Truist Financial

Buy

―

Reiterated

12/30/25

Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Owlet (OWLT)

Douglas Tsao

H.C. Wainwright

$340

Buy

24.59%

Upside

Reiterated

12/30/25

Compelling Risk‑Reward in Praxis Precision Medicines: Breakthrough Ulixacaltamide, Platform Upside, and $340 Target Price Support Buy Rating

Andrew Tsai

Jefferies

$450

Buy

64.90%

Upside

Reiterated

12/29/25

Breakthrough designation gives Praxis 'notable FDA validation,' says JefferiesBreakthrough designation gives Praxis 'notable FDA validation,' says Jefferies

Kambiz Yazdi

BTIG

$507→$843

Buy

208.90%

Upside

Reiterated

12/29/25

Praxis Precision Medicines: Ulixacaltamide’s Commercial Edge and 2026 Pipeline Catalysts Drive Substantial Upside to $843 Target

Francois Brisebois

LifeSci Capital

$420→$534

Buy

95.68%

Upside

Reiterated

12/29/25

Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating

Jay Olson

Oppenheimer

$250→$750

Buy

174.83%

Upside

Reiterated

12/15/25

Praxis Precision price target raised to $750 from $250 at OppenheimerPraxis Precision price target raised to $750 from $250 at Oppenheimer

David Hoang

Deutsche Bank

$303→$313

Buy

14.69%

Upside

Reiterated

12/12/25

Praxis Precision price target raised to $313 from $303 at Deutsche BankPraxis Precision price target raised to $313 from $303 at Deutsche Bank

Yasmeen Rahimi

Piper Sandler

$450

Buy

64.90%

Upside

Reiterated

12/10/25

Piper Sandler Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

Yatin Suneja

Guggenheim

$540→$760

Buy

178.49%

Upside

Reiterated

12/09/25

Praxis Precision price target raised to $760 from $540 at GuggenheimPraxis Precision price target raised to $760 from $540 at Guggenheim

Justin Walsh

JonesTrading

$441

Buy

61.60%

Upside

Reiterated

12/09/25

Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating

Laura Chico

Wedbush

$83

Sell

-69.59%

Downside

Reiterated

12/08/25

Praxis Precision price target raised to $83 from $77 at WedbushPraxis Precision price target raised to $83 from $77 at Wedbush

Brian Skorney

Robert W. Baird

$76→$275

Buy

0.77%

Upside

Reiterated

10/16/25

Praxis Precision price target raised to $275 from $76 at BairdPraxis Precision price target raised to $275 from $76 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ami Fadia

Needham

$315→$460

Buy

68.56%

Upside

Reiterated

01/05/26

Praxis Precision price target raised to $460 from $315 at NeedhamPraxis Precision price target raised to $460 from $315 at Needham

Ritu Baral

TD Cowen

$353

Buy

29.35%

Upside

Reiterated

12/31/25

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX)

Rudy Li

Chardan Capital

$330

Buy

20.92%

Upside

Initiated

12/31/25

Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital

Joon Lee

Truist Financial

Buy

―

Reiterated

12/30/25

Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Owlet (OWLT)

Douglas Tsao

H.C. Wainwright

$340

Buy

24.59%

Upside

Reiterated

12/30/25

Compelling Risk‑Reward in Praxis Precision Medicines: Breakthrough Ulixacaltamide, Platform Upside, and $340 Target Price Support Buy Rating

Andrew Tsai

Jefferies

$450

Buy

64.90%

Upside

Reiterated

12/29/25

Breakthrough designation gives Praxis 'notable FDA validation,' says JefferiesBreakthrough designation gives Praxis 'notable FDA validation,' says Jefferies

Kambiz Yazdi

BTIG

$507→$843

Buy

208.90%

Upside

Reiterated

12/29/25

Praxis Precision Medicines: Ulixacaltamide’s Commercial Edge and 2026 Pipeline Catalysts Drive Substantial Upside to $843 Target

Francois Brisebois

LifeSci Capital

$420→$534

Buy

95.68%

Upside

Reiterated

12/29/25

Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating

Jay Olson

Oppenheimer

$250→$750

Buy

174.83%

Upside

Reiterated

12/15/25

Praxis Precision price target raised to $750 from $250 at OppenheimerPraxis Precision price target raised to $750 from $250 at Oppenheimer

David Hoang

Deutsche Bank

$303→$313

Buy

14.69%

Upside

Reiterated

12/12/25

Praxis Precision price target raised to $313 from $303 at Deutsche BankPraxis Precision price target raised to $313 from $303 at Deutsche Bank

Yasmeen Rahimi

Piper Sandler

$450

Buy

64.90%

Upside

Reiterated

12/10/25

Piper Sandler Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

Yatin Suneja

Guggenheim

$540→$760

Buy

178.49%

Upside

Reiterated

12/09/25

Praxis Precision price target raised to $760 from $540 at GuggenheimPraxis Precision price target raised to $760 from $540 at Guggenheim

Justin Walsh

JonesTrading

$441

Buy

61.60%

Upside

Reiterated

12/09/25

Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating

Laura Chico

Wedbush

$83

Sell

-69.59%

Downside

Reiterated

12/08/25

Praxis Precision price target raised to $83 from $77 at WedbushPraxis Precision price target raised to $83 from $77 at Wedbush

Brian Skorney

Robert W. Baird

$76→$275

Buy

0.77%

Upside

Reiterated

10/16/25

Praxis Precision price target raised to $275 from $76 at BairdPraxis Precision price target raised to $275 from $76 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Praxis Precision Medicines

1 Month

xxx

Success Rate

13/17 ratings generated profit

Average Return

+12.05%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.47% of your transactions generating a profit, with an average return of +12.05% per trade.

3 Months

xxx

Success Rate

14/17 ratings generated profit

Average Return

+63.86%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 82.35% of your transactions generating a profit, with an average return of +63.86% per trade.

1 Year

Ami FadiaNeedham

Success Rate

12/15 ratings generated profit

Average Return

+271.82%

reiterated a buy rating 3 days ago

Copying Ami Fadia's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +271.82% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+397.80%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +397.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRAX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PRAX has received 41 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. PRAX average Analyst price target in the past 3 months is 455.86.

Each month's total comprises the sum of three months' worth of ratings.

PRAX Financial Forecast

PRAX Earnings Forecast

Next quarter’s earnings estimate for PRAX is -$3.09 with a range of -$4.16 to -$2.17. The previous quarter’s EPS was -$3.36. PRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Sales Forecast

Next quarter’s sales forecast for PRAX is $398.00K with a range of $0.00 to $2.98M. The previous quarter’s sales results were $0.00. PRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PRAX has Performed in-line its overall industry.

PRAX Stock Forecast FAQ

What is PRAX’s average 12-month price target, according to analysts?

Based on analyst ratings, Praxis Precision Medicines’s 12-month average price target is 455.86.

What is PRAX’s upside potential, based on the analysts’ average price target?

Praxis Precision Medicines has 67.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PRAX a Buy, Sell or Hold?

Praxis Precision Medicines has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 1 sell ratings.

What is Praxis Precision Medicines’s price target?

The average price target for Praxis Precision Medicines is 455.86. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $843.00 ,the lowest forecast is $83.00. The average price target represents 67.04% Increase from the current price of $272.9.

What do analysts say about Praxis Precision Medicines?

Praxis Precision Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of PRAX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Praxis Precision Medicines (PRAX) Stock Forecast & Price Target

PRAX Analyst Ratings

PRAX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Praxis Precision Medicines

PRAX Analyst Recommendation Trends

PRAX Financial Forecast

PRAX Earnings Forecast

PRAX Sales Forecast

PRAX Stock Forecast FAQ

Detailed List of Analyst Forecasts